BNSSG Adult Joint Formulary
10.5 Soft tissue and joint disorders
Checked: not set yet by Next Review: not set yet
10.5.1 Local inflammation of joints and soft tissue
|First line drugs||Second line drugs||Specialist drugs||Secondary care drugs|
- Treatment with corticosteroids in rheumatic diseases should be reserved for specific indications e.g. when other anti-inflammatory drugs are unsuccessful.
- Corticosteroids may reduce bone density and increase the risk of low impact fracture and can induce osteoporosis. Patients taking (or who are likely to take) an oral corticosteroid at an equivalent dose of 5mg prednisolone or more, for 3 months or longer should be assessed using the FRAX® algorithm and where necessary offered appropriate given prophylactic treatment. See BNF section 6.6
Prednisolone (TLS Green)
Methylprednisolone (TLS Blue)
Local Corticosteroid Injections
Hydrocortisone acetate (Hydrocortistab®) (TLS Green)
Triamcinolone acetonide (Kenalog®) (TLS Green)
Methylprednisolone acetate (Depo-Medrone®) (TLS Green)
Methylprednisolone acetate / Lidocaine (Depo-Medrone® with Lidocaine) (TLS Green)
10.5.2 Soft tissue disorders
Hyaluronidase (TLS Blue)
- Not the intra-articular preparation e.g. Synvisc®
Collagenase (TLS Red)
- NICE TA459 collagenase clostridium histolyticum for treating Dupuytren's contracture
Dibotermin alfa (TLS Red)
- In accordance with NHS England Clinical Commissioning Policy 16063/P
Got a question or comment about the Joint Formulary?
Please use the email address below to contact us and we will endeavour to respond within 2 working days.